Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials.

Alexander D SherryPavlos MsaouelAvital M MillerTimothy A LinGabrielle S KupfermanJoseph Abi JaoudeRamez KouzyMolly B El-AlamRoshal PatelAlex KoongChristine LinTomer MeirsonZachary Ryan McCawEthan B Ludmir

Published in: medRxiv : the preprint server for health sciences (2024)

Bayesian interim analysis may improve the efficiency of conducting randomized trials, leading to reduced costs, reduced exposure of patients to disadvantageous treatments, and accelerated approval of efficacious therapies.

Keyphrases

phase iii
end stage renal disease
chronic kidney disease
newly diagnosed
open label
prognostic factors
randomized controlled trial